A method and an apparatus for producing radionuclide-containing products having substantially the identical desired activity of radioactivity at different times of application, with respect to a given calibration time. The method according to the invention allows to ensure a consistent composition of the desired radionuclide-labeled pharmaceutical at all times of application within the shelf life through a single manufacturing process. With the present invention it is possible, for example, to provide [n.c.a. Lu-177]Lu-DOTATOC on each working day of the week with constant activity at the respective time of application in a single manufacturing step.

Disclosed is a method for preparing a strontium-82/rubidium-82 generator. The method includes: filling a column volume with a sorbent made of hydrated tin (IV) oxide; passing through the column an initial solution with strontium-82 radionuclide, which also contains ions of stable isotopes of calcium and strontium; and washing out rubidium-82 with a saline solution of 0.9% sodium chloride. In order to achieve a breakthrough of strontium-82 or strontium-85 below permissible levels, 0.01 and 0.1 kBq per 1 MBq .sup.82Rb, respectively, when passing not less than 17 liters of saline solution through columns with a volume of not less than 1.6 cm.sup.3 and a dry sorbent weight of not less than 3.8 g, a specific activity of strontium-82 in the initial solution is not less than 90 GBq (2400 mCi) per mg of stable strontium cations for a generator with an activity of 3700 MBq (100 mCi).

The present disclosure relates to the field of diagnostic methods, and more particularly prostate cancer imaging. In particular, the disclosure relates to a radiopharmaceutical PSMA-binding compound for use in determining the presence and/or localization of PSMA-positive tumors in a subject in need thereof, wherein said subject has been diagnosed with biochemical recurrence, particularly after radical prostatectomy or radiotherapy, and wherein said radiopharmaceutical compound is the compound of formula (III).

##STR00001##

A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.

The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.

The present disclosure relates to a composition for stabilizing the radiochemical purity of [.sup.18F]fluoro-dopa by inhibiting the formation of impurities during a predetermined time period, and a method for preparing the same. The composition according to the present disclosure includes: [.sup.18F]fluoro-dopa; ethanol in a concentration of 5% to 30%(v/v) relative to the total composition; and a buffer having a pKa value of 6 to 8.1 at 25 C., in which the composition stabilizes the radiochemical purity of the [.sup.18F]fluoro-dopa by inhibiting the formation of impurities during a predetermined time period.

Processes and compositions for 2-heteroaryl substituted benzofuran derivatives are described. The 2-heteroaryl substituted benzofuran derivatives may be suitable for preparing radiolabeled 2-heteroaryl substituted benzofuran derivatives for imaging amyloid deposits in living patients.

Methods for imaging beta cells in pancreatic tissue using radioisotopes of manganese, which may be referred to as radiomanganese, are described. Example radioisotopes of manganese include Mn-52g, Mn-52m, and Mn-51. As one example, radiomanganese can be used to image pancreatic beta cells, in which radiomanganese shows a preferential uptake. This provides for applications such as quantifying beta cell mass (e.g., functional beta cell mass), assessing transplant viability, and monitoring the efficacy of drug treatments. A pharmacological agent can be administered to modulate the uptake of divalent metals by the pancreatic beta cells, which can be correlated to a modulated uptake of radiomanganese to estimate pancreatic beta cell mass, function, or both.

The present disclosure is generally related to methods, systems and devices for direct production of a radioisotope-based cancer treatment pharmaceutical directly from a corresponding non-radioactive drug molecule precursor by irradiating the non-radioactive drug molecule precursor using neutrons produced by an electronic neutron generator array or other neutron generator sources.

Provided is a method of preparing an aqueous ascorbic acid solution having a pH of 2.0 to 4.0, the method comprising: providing an initial aqueous solution of ascorbic acid and a base, wherein the initial solution has a pH of 5.0 to 8.0; and combining the initial solution with a second acid to obtain an ascorbic acid solution having a pH of 2.0 to 4.0. Also provided is the use of an aqueous ascorbic acid solution having a pH of 2.0 to 4.0 prepared by a described method as a radiostabiliser of a radio-labelled compound.